Financial Performance - Astrana Health reported a significant increase in revenue, reaching $500 million, representing a 25% year-over-year growth[7]. - The company achieved an Adjusted EBITDA of $75 million, which is a 15% increase compared to the previous year[7]. - The company has set a future revenue guidance of $600 million for the next fiscal year, reflecting a 20% growth target[7]. - Astrana Health completed the acquisition of Prospect Medical Holdings, which is expected to contribute an additional $200 million in annual revenue[7]. User Growth and Satisfaction - User data showed a 30% increase in active users, totaling 1.2 million users, driven by enhanced service offerings[7]. - The company reported a 10% increase in patient satisfaction scores, indicating improved service quality[7]. Market Expansion and Investment - Astrana Health plans to expand its market presence by entering three new states in the next fiscal year, targeting a 20% market share in those regions[7]. - The company is investing $50 million in new product development, focusing on telehealth services and advanced diagnostic tools[7]. Risk Management and Forward-Looking Statements - The company emphasizes that all statements other than historical facts are considered "forward-looking statements" under federal and state securities laws[23]. - Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected[24]. - The company believes that the expectations reflected in its forward-looking statements are reasonable, but actual results could vary significantly[24]. - Significant risks and uncertainties could impact the company's future financial condition and results of operations[24]. - The company undertakes no obligation to publicly update any forward-looking statement unless required by applicable securities laws[24]. Healthcare Initiatives - Astrana Health is actively participating in the ACO REACH Model, aiming to improve healthcare access and equity[19]. Cybersecurity - Astrana Health is addressing cybersecurity risks by enhancing its IT infrastructure with a budget of $10 million for the upcoming year[7].

Core Insights - Astrana Health operates a unique single payer model, taking a reimbursement percentage of premium from both large national and regional payer partners, which allows for a unified multiline of business and a well-coordinated multi-payer downstream provider network that delivers better care at a lower cost [1] Group 1: Business Performance - The company has maintained profitability over the last 30 years and has experienced consistent growth [2] - Since the CEO joined the company 7 years ago, revenue has increased sixfold, and free cash flow has nearly increased eightfold [2] - The company continues to grow at a rapid pace, with a compound annual growth rate (CAGR) of 20% to 30% [2]

Core Insights - Astrana Health reported record revenue, adjusted EBITDA, and free cash flow for the fourth quarter and full year 2025, driven by the acquisition of Prospect Health and growth in value-based care membership [5][4] - The company aims for approximately 80% of revenue and over 36% of its membership to be in full-risk arrangements by the end of Q1 2026 [1][2] Financial Performance - Full-year revenue grew 56% year-over-year, reaching the high end of guidance, supported by organic growth and contributions from Prospect [3] - Free cash flow for 2025 was $104.5 million, reflecting over 50% conversion relative to adjusted EBITDA, with cash at $429.5 million and net debt at $648.7 million [14] Membership and Growth - By the end of 2025, Astrana served 1.6 million members in value-based care arrangements, with growth characterized as "measured" [2] - The company expects to achieve annualized synergies of $12 million to $15 million from the Prospect integration [10] Operational Efficiency - General and administrative expenses as a percentage of revenue decreased to 6.8% in 2025, down 75 basis points year-over-year [8] - Engagement and workflow automation are highlighted as key drivers of clinical and financial outcomes, with annual wellness visit completion rates approaching 80% [6] Technology and AI Investments - The company has over 100 U.S.-based data scientists and engineers working on a proprietary platform focused on automating various healthcare processes [9] - AI tools are aimed at improving prior authorizations, claims processing, and providing real-time insights for providers [9] 2026 Guidance - For Q1 2026, Astrana guided revenue between $900 million and $1.0 billion and adjusted EBITDA of $60 million to $70 million [15] - The guidance framework is described as deliberately prudent, considering headwinds such as expected declines in Medicaid enrollment and conservative medical cost assumptions [16] Cost Trends - The blended medical cost trend for 2025 was slightly ahead of expectations at mid-4%, with a conservative assumption of just over 5% for 2026 [17] - Medicare Advantage rates are expected to positively impact Astrana more than the industry average, with a potential increase of 2.5% to 3% [18] Capital Allocation - The company repurchased approximately 634,000 shares at an average price of $22.23, increasing the maximum authorization for share repurchase from $50 million to $100 million [14]

Core Insights - Astrana Health, Inc. reported record revenue, adjusted EBITDA, and free cash flow for the year 2025, demonstrating consistent performance despite regulatory changes and market volatility [5][7][28] - The company aims to build a leading patient-centered, payer-agnostic healthcare platform, focusing on delivering high-quality care at lower costs [5][6] - The growth strategy includes disciplined membership growth, measured risk progression, and leveraging technology to enhance operational efficiency [20][24] Financial Performance - In Q4 2025, total revenue reached $950.5 million, a 43% increase year-over-year, while adjusted EBITDA was $52.5 million, up 50% year-over-year [6][28] - For the full year 2025, revenue was $3.2 billion, representing a 56% year-over-year growth, with adjusted EBITDA totaling $205.4 million, a 21% increase [7][28] - Free cash flow for 2025 was $104.5 million, with a conversion rate exceeding 50% relative to adjusted EBITDA [29] Membership and Market Expansion - The company served 1.6 million members in value-based care arrangements by year-end 2025, with a focus on disciplined growth and strong provider engagement [9][11] - Revenue from California grew by 50% year-over-year, while revenue from markets outside California increased by 90% year-over-year [10] - Approximately 19% of total revenue was generated from membership outside California, indicating geographic diversification [11] Risk Management and Cost Control - Astrana Health has maintained disciplined risk progression, entering full-risk arrangements only when aligned with medical cost trends [11][12] - Medical cost trends remained well-controlled, with legacy Astrana Health performing slightly better than the projected 4.5% cost trend [14] - The company expects approximately 80% of its revenue and over 36% of owned membership to be in full-risk arrangements by Q1 2026 [13] Technology and Operational Efficiency - The company's technology platform has driven significant operating leverage, enabling capital-efficient growth and margin expansion [18][19] - G&A as a percentage of revenue was 6.8% in 2025, down 75 basis points year-over-year, reflecting improved operational efficiency [19] - AI tools are being developed to enhance care delivery, automate processes, and improve patient engagement [61][62] Future Outlook - For 2026, the company expects revenue between $3.8 billion and $4.1 billion, with adjusted EBITDA between $250 million and $280 million [31] - The guidance reflects a conservative approach, accounting for potential headwinds from Medicaid and exchange disenrollment [34] - The company anticipates continued growth driven by full-risk contracts, realization of synergies from the Prospect acquisition, and sustained cost discipline [31][34]

Financial Data and Key Metrics Changes - In Q4 2025, total revenue was $950.5 million, a 43% increase year-over-year, while adjusted EBITDA was $52.5 million, up 50% year-over-year [7][24] - For the full year 2025, revenue reached $3.2 billion, adjusted EBITDA totaled $205.4 million, and free cash flow was $104.5 million, each a record for the company [8][25] - Since 2019, revenue has grown by 467%, representing a 34% compound annual growth rate, while adjusted EBITDA increased by 279% or 25% annually [8][9] Business Line Data and Key Metrics Changes - The company ended 2025 serving 1.6 million members in value-based care arrangements, with a mid-single-digit growth in Medicare Advantage membership year-over-year [9][10] - California revenue grew 50% year-over-year, while revenue outside California grew 90% year-over-year, indicating strong performance in both core and expansion markets [10][11] Market Data and Key Metrics Changes - Approximately 19% of total revenue was generated from membership outside California, reflecting geographic diversification [10] - The company expects approximately 80% of its revenue and more than 36% of its membership to be in full risk arrangements by Q1 2026 [12] Company Strategy and Development Direction - The company aims to build a leading patient-centered, payer-agnostic healthcare platform, focusing on high-quality, accessible care [5][6] - The strategy includes disciplined membership growth, measured risk progression, and leveraging technology for operational efficiency [17][22] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate regulatory changes and market volatility, emphasizing the strength of its care model and technology platform [21][22] - The company anticipates continued disciplined membership growth and stable medical cost performance into 2026 [22][29] Other Important Information - The company is addressing a material weakness in internal controls over financial reporting related to acquisition processes, with no material misstatement reported [23] - The board has increased the maximum share repurchase amount from $50 million to $100 million, reflecting confidence in long-term business value [27][28] Q&A Session Summary Question: Expectations of cost trends for 2026 - Management expects a conservative cost trend of just over 5% for 2026, with Medicare Advantage slightly lower and Medicaid and Commercial slightly higher [33][35] Question: Clarification on 2026 EBITDA guidance range - The guidance range reflects a consistent percentage of the midpoint, with expected contributions from Prospect synergies and forward contract rates [37][40] Question: Impact of Medicare Advantage rate notice on 2027 targets - Management believes the company will be less impacted by the rate notice compared to the industry, expecting a positive 2.5%-3% impact on rates [46][48] Question: Member engagement metrics post-Propect integration - Management noted strong engagement metrics, with expectations for improved annual wellness visit rates due to integrated care processes [73][75] Question: Nature of AI tools and their impact - The company is developing AI tools to enhance operational efficiency and reduce costs, focusing on automating payer-related functions and improving provider access to real-time data [59][62]

Financial Data and Key Metrics Changes - In Q4 2025, total revenue was $950.5 million, a 43% increase year-over-year, while adjusted EBITDA was $52.5 million, up 50% year-over-year [7][24] - For the full year 2025, revenue reached $3.2 billion, adjusted EBITDA totaled $205.4 million, and free cash flow was $104.5 million, each a record for the company [8][25] - Since 2019, revenue has grown by 467%, representing a 34% compound annual growth rate, while adjusted EBITDA increased by 279% or 25% annually [8][9] Business Line Data and Key Metrics Changes - Membership in value-based care arrangements reached 1.6 million, with mid-single-digit growth in Medicare Advantage membership year-over-year [9][10] - California revenue grew 50% year-over-year, while revenue outside California grew 90% year-over-year, indicating strong performance in both core and expansion markets [10][11] Market Data and Key Metrics Changes - Approximately 19% of total revenue was generated from membership outside California, reflecting geographic diversification [10] - The company expects approximately 80% of revenue and more than 36% of membership to be in full risk arrangements by the end of Q1 2026 [12] Company Strategy and Development Direction - The company aims to build a leading patient-centered, payer-agnostic healthcare platform, focusing on high-quality, accessible care [5][6] - The strategy includes disciplined membership growth, measured risk progression, and leveraging technology for operational efficiency [17][22] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate regulatory changes and market volatility, emphasizing the strength of its care model and technology platform [21][22] - The company anticipates continued disciplined membership growth and stable medical cost performance into 2026, with revenue guidance between $3.8 billion and $4.1 billion [29][30] Other Important Information - The company is addressing a material weakness in internal controls over financial reporting related to acquisition processes, with no material misstatement reported [23] - The board has increased the maximum share repurchase amount from $50 million to $100 million, reflecting confidence in long-term business value [27][28] Q&A Session Summary Question: Expectations of cost trends for 2026 - Management expects a conservative cost trend of just over 5% for 2026, with Medicare Advantage slightly lower and Medicaid and Commercial slightly higher [33][35] Question: Clarification on 2026 EBITDA guidance range - The guidance range reflects a consistent percentage of the midpoint, with expected contributions from Prospect Health synergies and forward contract rates [37][42] Question: Impact of Medicare Advantage rate notice on 2027 targets - Management believes the company will be less impacted by the rate notice compared to the industry, expecting a positive 2.5%-3% impact [46][49] Question: Integration and revenue from Prospect Health - Approximately 10%-15% of Prospect revenue is fee-for-service, with strong provider engagement and retention [55][56] Question: AI tools and their impact on operations - The company is developing AI tools to improve efficiency and reduce administrative burdens, which are expected to enhance performance and scalability [59][62] Question: Care Enablement business pipeline and margins - The Care Enablement business has a strong pipeline, with expected EBITDA margins in the 20%-25% range going forward [67]

Financial Data and Key Metrics Changes - In Q4 2025, total revenue reached $950.5 million, a 43% increase year-over-year. Adjusted EBITDA was $52.5 million, up 50% year-over-year [5][24] - For the full year 2025, revenue was $3.2 billion, representing a 56% year-over-year growth. Adjusted EBITDA totaled $205.4 million, up 21% year-over-year [6][24] - Free cash flow for the full year was $104.5 million, with a conversion rate exceeding 50% relative to adjusted EBITDA [25] Business Line Data and Key Metrics Changes - Membership in value-based care arrangements reached 1.6 million, with mid-single-digit growth in Medicare Advantage membership year-over-year [8] - California revenue grew 50% year-over-year, while revenue outside California increased by 90% year-over-year [9] - The company expects approximately 80% of revenue and over 36% of membership to be in full risk arrangements by Q1 2026 [11] Market Data and Key Metrics Changes - The company reported strong provider engagement with over 97% gross retention among Prospect primary care physicians [17] - Medical cost trends remained well controlled, with legacy Astrana performing slightly better than the projected 4.5% cost trend [12][24] - The company anticipates approximately 10%-15% Medicaid disenrollments and low double-digit declines in HICS [71] Company Strategy and Development Direction - The company aims to build a leading patient-centered, payer-agnostic healthcare platform, focusing on high-quality, accessible care [4] - The strategy includes disciplined membership growth, measured risk progression, and leveraging technology for operational efficiency [16][20] - The integration of Prospect Health is on track, with expected annualized synergies of $12 million-$15 million [17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate regulatory changes and maintain growth, emphasizing the strength of its clinical infrastructure and technology platform [19][20] - The company expects continued disciplined membership growth and stable medical cost performance in 2026 [20][27] - Management highlighted the importance of operational excellence in a complex environment, which has allowed the company to expand its competitive position [5][10] Other Important Information - The company is addressing a material weakness in internal controls over financial reporting related to acquisition processes, with no material misstatement reported [22] - The board has increased the stock repurchase program from $50 million to $100 million, reflecting confidence in long-term value [26] Q&A Session Summary Question: Expectations of cost trends for 2026 - Management expects a conservative cost trend of just over 5% for 2026, slightly higher than the previous year due to potential Medicaid disenrollments [32][34] Question: Clarification on 2026 EBITDA guidance range - Management provided a breakdown of expected contributions to EBITDA, including synergies from Prospect and improvements from expansion markets [36][41] Question: Impact of Medicare Advantage rate notice on 2027 targets - Management believes the company will be less impacted by the Medicare Advantage rate notice compared to the industry, expecting a positive 2.5%-3% impact [43][47] Question: Member engagement metrics post-Propect integration - Management noted that while it is early, they expect strong annual wellness visit engagement and quality score growth in the legacy Prospect business [74][76] Question: Seasonality in guidance and M&A plans - Management indicated that there is no planned M&A in the current guidance and expects the third quarter to be stronger than others [79]

分组1 - Astrana Health, Inc. reported quarterly earnings of $0.54 per share, significantly exceeding the Zacks Consensus Estimate of $0.15 per share, and compared to a loss of $0.15 per share a year ago, representing an earnings surprise of +252.25% [1] - The company posted revenues of $950.53 million for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 2.89%, and this is an increase from year-ago revenues of $665.21 million [2] - Astrana Health, Inc. shares have declined approximately 18.1% since the beginning of the year, while the S&P 500 has gained 0.5% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is $0.20 on revenues of $905.4 million, and for the current fiscal year, it is $1.00 on revenues of $3.86 billion [7] - The Zacks Industry Rank for Medical - Outpatient and Home Healthcare is currently in the bottom 27% of over 250 Zacks industries, indicating potential underperformance compared to higher-ranked industries [8]

Fourth Quarter & Full Year 2025 March 2026 Earnings Supplement Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act and Section 21E of the Exchange Act. Forward-looking statements include any statements about the Company's business, financial condition, operating results, plans, objectives, expectations and intentions, expansion plans, estimates of our total addressable m ...

Financial Performance - Total revenue for the year ended December 31, 2025, was $3,181.8 million, representing a 56% increase year-over-year[5] - Adjusted EBITDA for the year was $205.4 million, up 21% from $170.4 million[5] - Care Partners revenue was $3,022.6 million, an increase of 55% from $1,949.0 million[5] - Total revenue for the year ended December 31, 2025, increased to $3,181.8 million, up 56.3% from $2,034.5 million in 2024[26] - Net income attributable to Astrana Health, Inc. for the year ended December 31, 2025, was $22.5 million, a decrease of 48.1% compared to $43.1 million in 2024[26] - Earnings per share (diluted) for the year ended December 31, 2025, were $0.46, down from $0.90 in 2024[26] - Net income for the year ended December 31, 2025 was $24,076,000, down from $49,932,000 in 2024, while net income for the three months ended December 31, 2025 was $6,562,000 compared to a loss of $7,777,000 in the same period of 2024[32] Cash Flow and Assets - Free cash flow for the year reached $104.5 million[1] - Cash and cash equivalents as of December 31, 2025, were $429.5 million, an increase of 48.9% from $288.5 million in 2024[29] - The company reported a net cash provided by operating activities of $114.6 million for the year ended December 31, 2025, compared to $52.2 million in 2024[28] - Net cash provided by operating activities increased to $114,597,000 in 2025 from $52,198,000 in 2024, resulting in free cash flow of $104,491,000 compared to $44,167,000 in the previous year[30] Guidance and Projections - The company expects approximately 24% revenue growth and 29% adjusted EBITDA growth at the midpoint for 2026[2] - Guidance for total revenue for the year ending December 31, 2026, is projected between $3,800 million and $4,100 million[14] - Adjusted EBITDA guidance for the year ending December 31, 2026, is projected between $250 million and $280 million[14] - The company provided guidance for 2026, projecting net income between $54,000,000 and $74,000,000 and adjusted EBITDA between $250,000,000 and $280,000,000[41] Shareholder Actions - The Board of Directors increased the share repurchase program from $50 million to $100 million[9] - During Q4 2025, the company repurchased 633,844 shares under the share repurchase plan[10] Operational Metrics - Operating expenses for the year ended December 31, 2025, were $3,103.2 million, a significant increase of 59.3% from $1,945.2 million in 2024[26] - Stock-based compensation for the year ended December 31, 2025 was $38,601,000, compared to $34,536,000 in 2024[37] - Other net expenses for the year ended December 31, 2025 included $25.9 million for transaction and integration costs primarily related to the acquisition of Prospect[34] - The company reported interest expense of $49,928,000 for the year ended December 31, 2025, an increase from $33,097,000 in 2024[32] Balance Sheet - Total assets grew to $2,218.7 million as of December 31, 2025, compared to $1,354.9 million in 2024, reflecting a 63.8% increase[24] - Total liabilities increased to $1,660.3 million as of December 31, 2025, up 97.4% from $840.7 million in 2024[24] - The company’s total stockholders' equity increased to $793.3 million as of December 31, 2025, from $716.7 million in 2024, reflecting a growth of 10.7%[24] Internal Controls - The company is addressing a material weakness in internal control over financial reporting but does not expect any material misstatement of financial results[8] Taxation - Tax adjustments for the year ended December 31, 2025 amounted to $33.3 million, reflecting a 27.1% statutory blended tax rate[38] Share Metrics - The weighted average shares of common stock outstanding for diluted earnings per share increased to 49,527,521 in the three months ended December 31, 2025 from 47,823,360 in the same period of 2024[37]